CL2016000695A1 - Un inhibidor selectivo de la fosfatidilinositol 3-quinasa-gamma - Google Patents

Un inhibidor selectivo de la fosfatidilinositol 3-quinasa-gamma

Info

Publication number
CL2016000695A1
CL2016000695A1 CL2016000695A CL2016000695A CL2016000695A1 CL 2016000695 A1 CL2016000695 A1 CL 2016000695A1 CL 2016000695 A CL2016000695 A CL 2016000695A CL 2016000695 A CL2016000695 A CL 2016000695A CL 2016000695 A1 CL2016000695 A1 CL 2016000695A1
Authority
CL
Chile
Prior art keywords
kinase
gamma inhibitor
selective
selective phosphatidylinositol
piridin
Prior art date
Application number
CL2016000695A
Other languages
English (en)
Inventor
Alex Aronov
Jeremy Green
Michael John Boyd
Hardwin O'dowd
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CL2016000695A1 publication Critical patent/CL2016000695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>COMPUESTO (R)-6-(1-(2,2-DIFLUOROETIL)-1H-PIRAZOL-4-IL)-4,7,7-TRIMETIL-2-(5-(2,2,2-TRIFLUORO-1-HIDROXIETIL)-PIRIDIN-3-IL)-6,7-DIHIDRO-5H-PIRROLO[3,4-B]PIRIDIN-5-ONA, INHIIBIDOR SELECTIVO DE FOSFATIDILINOSITOL 3-QUINASA-GAMMA (PI3Kγ); COMPOSICION FARMACEUTICA; METODO PARA TRATAR ASMA, RINITIS Y PSORIASIS, ENTRE OTRAS ENFERMEDADES. </p>
CL2016000695A 2013-09-25 2016-03-24 Un inhibidor selectivo de la fosfatidilinositol 3-quinasa-gamma CL2016000695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361882473P 2013-09-25 2013-09-25

Publications (1)

Publication Number Publication Date
CL2016000695A1 true CL2016000695A1 (es) 2017-06-09

Family

ID=51795739

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000695A CL2016000695A1 (es) 2013-09-25 2016-03-24 Un inhibidor selectivo de la fosfatidilinositol 3-quinasa-gamma

Country Status (18)

Country Link
US (1) US10301304B2 (es)
EP (2) EP3412668B1 (es)
JP (1) JP6340416B2 (es)
KR (1) KR20160058950A (es)
CN (1) CN105722838B (es)
AU (1) AU2014324873B2 (es)
BR (1) BR112016006388A2 (es)
CA (1) CA2925601C (es)
CL (1) CL2016000695A1 (es)
ES (2) ES2785053T3 (es)
HK (1) HK1223620A1 (es)
IL (1) IL244742A0 (es)
MX (1) MX2016003823A (es)
RU (2) RU2018142605A (es)
SG (2) SG11201602265PA (es)
UA (1) UA117032C2 (es)
WO (1) WO2015048318A1 (es)
ZA (1) ZA201702252B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112016007467B1 (pt) 2013-10-04 2022-09-20 Infinity Pharmaceuticals, Inc Compostos heterocíclicos e usos dos mesmos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6786529B2 (ja) * 2015-06-29 2020-11-18 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
MX2018003058A (es) 2015-09-14 2018-08-01 Infinity Pharmaceuticals Inc Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
WO2017153527A1 (en) * 2016-03-10 2017-09-14 Astrazeneca Ab Novel inhibitors of phosphatidylinositol 3-kinase gamma
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2020210379A1 (en) 2019-04-10 2020-10-15 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5721187B2 (ja) * 2009-12-22 2015-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ホスファチジルイノシトール３−キナーゼのイソインドリノンインヒビター

Also Published As

Publication number Publication date
EP3412668A2 (en) 2018-12-12
ES2687593T3 (es) 2018-10-26
SG11201602265PA (en) 2016-04-28
HK1223620A1 (zh) 2017-08-04
CN105722838B (zh) 2017-10-24
EP3049415B1 (en) 2018-07-04
UA117032C2 (uk) 2018-06-11
EP3412668B1 (en) 2020-02-05
JP2016531861A (ja) 2016-10-13
CN105722838A (zh) 2016-06-29
RU2675814C2 (ru) 2018-12-25
BR112016006388A2 (pt) 2017-08-01
RU2018142605A (ru) 2019-02-04
CA2925601C (en) 2022-11-01
ZA201702252B (en) 2019-06-26
CA2925601A1 (en) 2015-04-02
MX2016003823A (es) 2016-08-01
AU2014324873B2 (en) 2018-11-08
IL244742A0 (en) 2016-04-21
EP3049415A1 (en) 2016-08-03
US10301304B2 (en) 2019-05-28
EP3412668A3 (en) 2018-12-19
SG10201802061TA (en) 2018-05-30
WO2015048318A1 (en) 2015-04-02
US20160214980A1 (en) 2016-07-28
KR20160058950A (ko) 2016-05-25
RU2016115726A3 (es) 2018-06-20
ES2785053T3 (es) 2020-10-05
JP6340416B2 (ja) 2018-06-06
AU2014324873A1 (en) 2016-04-21
RU2016115726A (ru) 2017-10-30

Similar Documents

Publication Publication Date Title
CL2016000695A1 (es) Un inhibidor selectivo de la fosfatidilinositol 3-quinasa-gamma
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
CL2017001930A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
CL2016000241A1 (es) Formulación de inhibidores de la syk.
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
DK3077397T3 (da) 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
CO6761389A2 (es) Inhibidores de nampt y rock
CL2012003602A1 (es) Compuestos heterociclicos nitrogenados fusionados, moduladores de fosfodiesterasas; un medicamento; un método para prevenir o tratar la esquizofrenia; y su uso para la produccion de un agente para prevenir o tratar la esquizofrenia.
DOP2011000260A (es) Pirimidinas fusionadas
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EP3064567A4 (en) Tool for vitrifying cryopreservation of cells or tissue
WO2014153495A3 (en) Novel stat3 inhibitors
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
EA201890821A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac